The Nexvax2 vaccine reprograms the disease-causing T-cells activated by an immune response to gluten in an approach similar to treatment for other allergies. The treatment reduces inflammation in the villi that line the small intestine.
The funding will go toward clinical trials to demonstrate proof-of-concept, and ImmusanT expects to start the next clinical trial in 2012.
Related Articles on Celiac Disease:
Specialists Urge Close Lymphoma Screening for Celiac Patients Due to High Risk
Celiac Disease Treatment Differs Between Physicians and Academics
Celiac Cases Rising, Cause Unknown
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
